PROGENICS PHARMACEUTICALS INC
- Headquarters
- TARRYTOWN, NY
- Latest Form D
- $12.9M, Jan 2013
- Total capital
- $57.3M
- Federal grants
- $44.3M
- 72 awards · 1996–2011
- Private capital raised
- $12.9M
- 1 Form D · last Jan 2013
- 165 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 14
- 26 pending · first 2014
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$12.9M
- Federal grantHealth and Human S · R01 · PA-50/PA-41 antitoxin antibody therapy for C. difficile infection$1.1M
- Federal grantHealth and Human S · R01 · PA-50/PA-41 antitoxin antibody therapy for C. difficile infection$1.1M
- Federal grantHealth and Human S · RC4 · Novel, Non-antibiotic Therapy for Clostridium difficile-Associated Disease$4.1M
- Federal grantHealth and Human S · U19 · HIV-1 Therapy with CCR5 mAB PRO 140-Overview$415K
- Federal grantHealth and Human S · P01 · HIV-1 Env Vaccine Design$740K
- Federal grantHealth and Human S · U19 · HIV-1 Therapy with CCR5 mAB PRO 140-Overview$581K
Show 66 earlier federal awards
- Federal grantHealth and Human S · P01 · Structure and Immunogenicity of Cleaved, Stabilized HIV-1 Envelope Trimers$2.9M
- Federal grantHealth and Human S · P01 · Structure and Immunogenicity of Cleaved, Stabilized HIV-1 Envelope Trimers$142K
- Federal grantHealth and Human S · U19 · HIV Entry Inhibitor Therapy with the CCR5 mAb PRO 140$402K
- Federal grantHealth and Human S · Phase I · Broadly Neutralizing MAbs against Hepatitis C Virus$351K
- Federal grantHealth and Human S · Phase I · Broadly Neutralizing MAbs against Hepatitis C Virus$287K
- Federal grantHealth and Human S · Phase I · Novel small-molecule inhibitors of HIV-1 Vif$300K
- Federal grantHealth and Human S · Phase I · Novel small-molecule inhibitors of HIV-1 Vif$291K
- Federal grantHealth and Human S · U19 · Viral Host And Combinational Influences on PRO 140$434K
- Federal grantHealth and Human S · Phase I · Broadly Inhibitory MAbs Targeting Hepatitis C Virus Receptors$306K
- Federal grantHealth and Human S · Phase I · Broadly Inhibitory MAbs Targeting Hepatitis C Virus Receptors$312K
- Federal grantHealth and Human S · Phase I · Developement of an alphavirus vaccine for melanoma$299K
- Federal grantHealth and Human S · Phase I · Developement of an alphavirus vaccine for melanoma$316K
- Federal grantHealth and Human S · U19 · HIV Entry Inhibitor Therapy with the CCR5 mAb PRO 140$692K
- Federal grantHealth and Human S · U19 · Tropism, Susceptibility and Resistance Deteminants$117K
- Federal grantHealth and Human S · Phase I · PRO 542 Immunotherapy of Advanced HIV 1 Disease$300K
- Federal grantHealth and Human S · Phase I · PRO 542 Immunotherapy of Advanced HIV 1 Disease$291K
- Federal grantHealth and Human S · Phase II · Development of PSMA -based recombinant protein vaccines$900K
- Federal grantHealth and Human S · Phase II · Development of PSMA -based recombinant protein vaccines$948K
- Federal grantHealth and Human S · Phase II · Development of PSMA -based recombinant protein vaccines$895K
- Federal grantHealth and Human S · Phase II · Development of PSMA -based recombinant protein vaccines$891K
- Federal grantHealth and Human S · Phase I · PSMA-Targeted Immunotoxins for Prostate Cancer Therapy$281K
- Federal grantHealth and Human S · Phase II · PSMA Antibody-Drug Conjugate for Prostate Cancer Therapy$467K
- Federal grantHealth and Human S · Phase I · PSMA-Targeted Immunotoxins for Prostate Cancer Therapy$269K
- Federal grantHealth and Human S · Phase II · PSMA Antibody-Drug Conjugate for Prostate Cancer Therapy$474K
- Federal grantHealth and Human S · Phase I · CCR5 inhibitors that block HIV but not chemokines$314K
- Federal grantHealth and Human S · Phase I · CCR5 inhibitors that block HIV but not chemokines$304K
- Federal grantHealth and Human S · Phase I · PSMA-KLH Conjugate Vaccines for Prostate Cancer$264K
- Federal grantHealth and Human S · Phase I · Novel Human Anti-CD19 Antibodies for Lymphoma Therapy$215K
- Federal grantHealth and Human S · Phase I · Novel Human Anti-CD19 Antibodies for Lymphoma Therapy$259K
- Federal grantHealth and Human S · Phase I · PSMA-KLH Conjugate Vaccines for Prostate Cancer$227K
- Federal grantHealth and Human S · Phase I · Development of Anti-PSMA Antibodies for Prostate Cancer$197K
- Federal grantHealth and Human S · Phase I · Alphavirus prime-boost vaccines for prostate cancer$181K
- Federal grantHealth and Human S · Phase II · PSMA-VRP vaccine for prostate cancer$459K
- Federal grantHealth and Human S · Phase I · Alphavirus prime-boost vaccines for prostate cancer$185K
- Federal grantHealth and Human S · Phase II · PSMA-VRP vaccine for prostate cancer$575K
- Federal grantHealth and Human S · Phase I · Development of Hepatitis C Virus entry inhibitors$294K
- Federal grantHealth and Human S · Phase I · Development of Hepatitis C Virus entry inhibitors$300K
- Federal grantHealth and Human S · Phase I · Human Anti-PSMA Antibodies for Prostate Cancer Therapy$196K
- Federal grantHealth and Human S · Phase II · Human PSMA MAb Radioimmunotherapy for Prostate Cancer$962K
- Federal grantHealth and Human S · Phase II · Human PSMA MAb Radioimmunotherapy for Prostate Cancer$892K
- Federal grantHealth and Human S · Phase II · Human PSMA MAb Radioimmunotherapy for Prostate Cancer$1M
- Federal grantHealth and Human S · Phase II · Human PSMA MAb Radioimmunotherapy for Prostate Cancer$971K
- Federal grantHealth and Human S · Phase I · Human Anti-PSMA Antibodies for Prostate Cancer Therapy$175K
- Federal grantHealth and Human S · Phase I · Development of PSMA-based Vaccines for Prostate Cancer$100K
- Federal grantHealth and Human S · Phase I · Novel Inhibitors of HIV-1 Reverse Transcriptase$256K
- Federal grantHealth and Human S · Phase I · Novel Inhibitors of HIV-1 Reverse Transcriptase$345K
- Federal grantHealth and Human S · Phase II · Development of Hepatitis C Virus Inhibitors$1M
- Federal grantHealth and Human S · Phase II · Development of Hepatitis C Virus Inhibitors$997K
- Federal grantHealth and Human S · Phase II · Development of Hepatitis C Virus Inhibitors$1M
- Federal grantHealth and Human S · Phase I · Dehydroascorbic Acid As Therapy For Ischemic Stroke$297K
- Federal grantHealth and Human S · Phase I · Development of Small-Molecule HIV Entry Inhibitors$300K
- Federal grantHealth and Human S · Phase II · Development of Small-Molecule HIV Entry Inhibitors$874K
- Federal grantHealth and Human S · Phase II · Development of Small-Molecule HIV Entry Inhibitors$833K
- Federal grantHealth and Human S · Phase I · CCR5 Sulfopeptides:A New Class of HIV Entry Inhibitors$300K
- Federal grantHealth and Human S · Phase II · Development of Small-Molecule HIV Entry Inhibitors$899K
- Federal grantHealth and Human S · Phase II · Humanized PRO 140 for CCR5-Targeted Therapy of HIV$924K
- Federal grantHealth and Human S · Phase II · Humanized PRO 140 for CCR5-Targeted Therapy of HIV$1M
- Federal grantHealth and Human S · Phase I · Pa 14 Coreceptor-targeted Immunotherapy Of Hiv Infection$300K
- Federal grantHealth and Human S · Phase II · Humanized PRO 140 for CCR5-Targeted Therapy of HIV$1.1M
- Federal grantHealth and Human S · Phase I · Transgenic Production Of CD4-IGG2 For Hiv Therapy$300K
- Federal grantHealth and Human S · Phase II · Transgenic Production of CD4-IgG2 for HIV Therapy$640K
- Federal grantHealth and Human S · Phase II · Transgenic Production of CD4-IgG2 for HIV Therapy$1M
- Federal grantHealth and Human S · Phase II · Transgenic Production of CD4-IgG2 for HIV Therapy$1M
- Federal grantHealth and Human S · R01 · Clinical Trials Of CD4 IGG2 And Humab Combinations$546K
- Federal grantHealth and Human S · R01 · Clinical Trials Of CD4 IGG2 And Humab Combinations$546K
- Federal grantHealth and Human S · Phase II · Development Of Antico Receptor Mabs For Hiv Therapy$813K
Federal awards are summed by year (72 awards); hover a bar for the split. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
197months
from PROGENICS PHARMACEUTICALS INC’s first federal award to its first private round.
- First federal award · Aug 1996
- Health and Human S · $813K
- First Form D · Jan 2013
- $12.9M · 1st Form D
- Awards before first raise
- 72 awards
An association in public records, not a cause or a prediction.
Founders and team
Researcher links verified by same-company patents and grants- Mark R. BakerResearcherExecutive Officer, DirectorLinked by 4 patents
- Paul J. MaddonResearcherDirectorLinked by $2.6M in grants as PI
- William C. OlsonResearcherExecutive OfficerLinked by $14.6M in grants as PI
- Charles A. BakerDirectorNamed in SEC Form D filings
- David A. ScheinbergDirectorNamed in SEC Form D filings
- Kurt W. BrinerDirectorNamed in SEC Form D filings
Show all 10 people
- Nicole S. WilliamsDirectorNamed in SEC Form D filings
- Peter J. CrowleyDirectorNamed in SEC Form D filings
- Robert J. IsraelExecutive OfficerNamed in SEC Form D filings
- Stephen P. GoffDirectorNamed in SEC Form D filings
What it has protected
USPTO · 14 granted of 40- GrantedNetwork For Medical Image Analysis, Decision Support System, And Related Graphical User Interface (gui) ApplicationsUSPTOUS 12,431,246
- GrantedNetwork For Medical Image Analysis, Decision Support System, And Related Graphical User Interface (gui) ApplicationsUSPTOUS 12,224,067
- PendingSynthesis Of The Prostate Specific Membrane Antigen (psma) Radiolabeled Inhibitor [18F]DCFPYLUSPTOApplication 18744219
Show all 40 patent records
- Network For Medical Image Analysis, Decision Support System, And Related Graphical User Interface (gui) ApplicationsSep 30, 2025 · US 12,431,246Granted
- Network For Medical Image Analysis, Decision Support System, And Related Graphical User Interface (gui) ApplicationsFeb 11, 2025 · US 12,224,067Granted
- Synthesis Of The Prostate Specific Membrane Antigen (psma) Radiolabeled Inhibitor [18F]DCFPYLJan 16, 2025 · Application 18744219Pending
- Systems And Methods For Secure Cloud-based Medical Image Upload And ProcessingJul 9, 2024 · US 12,032,722Granted
- Systems And Methods For Interactive Adjustment Of Intensity Windowing In Nuclear Medicine ImagesApr 2, 2024 · US 11,948,283Granted
- Network For Medical Image Analysis, Decision Support System, And Related Graphical User Interface (gui) ApplicationsFeb 6, 2024 · US 11,894,141Granted
- Systems And Methods For Assessing Disease Burden And ProgressionDec 21, 2023 · Application 18207246Pending
- Methods Of Making Prostate Cancer Treatment DecisionsAug 31, 2023 · Application 18094898Pending
- Systems And Methods For Secure Cloud-based Medical Image Upload And ProcessingJan 3, 2023 · US 11,544,407Granted
- Network For Medical Image Analysis, Decision Support System, And Related Graphical User Interface (gui) ApplicationsAug 23, 2022 · US 11,424,035Granted
- Combination Therapy For Treating Metastatic Prostate CancerOct 28, 2021 · Application 17227024Pending
- Methods Of Making Prostate Cancer Treatment DecisionsOct 28, 2021 · Application 17227048Pending
- Network For Medical Image Analysis, Decision Support System, And Related Graphical User Interface (gui) ApplicationsSep 1, 2020 · US 10,762,993Granted
- Network For Medical Image Analysis, Decision Support System, And Related Graphical User Interface (gui) ApplicationsMay 26, 2020 · US 10,665,346Granted
- Stable Pharmaceutical Formulations Of MethylnaltrexoneNov 28, 2019 · Application 16440304Pending
- Stable Pharmaceutical Formulations Of MethylnaltrexoneAug 13, 2019 · US 10,376,584Granted
- Network For Medical Image Analysis, Decision Support System, And Related Graphical User Interface (gui) ApplicationsJul 2, 2019 · US 10,340,046Granted
- Stable Pharmaceutical Formulations Of MethylnaltrexoneJun 6, 2017 · US 9,669,096Granted
- Synthesis Of (r)-n-methylnaltrexoneMay 25, 2017 · Application 15427420Pending
- Synthesis Of (r)-n-methylnaltrexoneMar 21, 2017 · US 9,597,327Granted
- Antibodies For The Treatment Of Clostridium Difficile-associated Infection And DiseaseJun 25, 2015 · Application 14642342Pending
- Synthesis Of (r)-n-methylnaltrexoneFeb 26, 2015 · Application 14218585Pending
- Formulations For Parenteral Delivery Of Compounds And Uses ThereofJan 22, 2015 · Application 14105805Pending
- Preparation And Use Of (R),(R)-2,2'-BIS-METHYLNALTREXONEDec 23, 2014 · US 8,916,706Granted
- Synthesis Of R-n-methylnaltrexoneDec 5, 2013 · Application 13670846Pending
- Antiviral PyrimidinesApplication PCTUS2010030598Pending
- Phosphatidylinositol 3 Kinase InhibitorsApplication PCTUS2009047970Pending
- Methods Of Inhibiting Infection By Diverse Subtypes Of Drug-resistant HIV-1Application PCTUS2009002654Pending
- Morphinan Derivatives Of Organic And Inorganic AcidsApplication PCTUS2009041722Pending
- Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods ThereofApplication PCTUS2008013964Pending
- Methods Of Inhibiting Infection By Diverse Subtypes Of Drug-resistant HIV-1Application PCTUS2008008752Pending
- N-oxides Of 4,5-EPOXY-MORPHINANIUM AnalogsApplication PCTUS2008064412Pending
- Methods For Reducing Viral Load In Hiv-infected PatientsApplication PCTUS2008005564Pending
- Peripheral Opioid Receptor Antagonists And Uses ThereofApplication PCTUS2008004109Pending
- Crystal Forms And Uses ThereofApplication PCTUS2008004116Pending
- Preparation And Use OF(R),(R)-2,2'-BIS-METHYLNALTREXONEApplication PCTUS2008001660Pending
- Preparation And Use Of (r)- 8- Keto-methylnaltrexoneApplication PCTUS2008001659Pending
- 7,8-SATURATED-4,5-EPOXY-MORPHINANIUM AnalogsApplication PCTUS2007085461Pending
- N-oxides Of 4,5-EPOXY-MORPHINANIUM AnalogsApplication PCTUS2007085428Pending
- (r)-n-stereoisomers Of 7,8-SATURATED-4,5-EPOXY-MORPHINANIUM AnalogsApplication PCTUS2007085458Pending
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .